Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Nature Reviews. Cancer|June 23, 2007
Targeting the protein kinase C family: are we there yet?Helen J Mackay, Christopher J TwelvesExpert Review of Anticancer Therapy|July 13, 2002
Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514)Robert J Jones, Christopher J TwelvesJournal of Public Health (Oxford, England)|February 1, 2013
A qualitative investigation of the motivations, experiences and views of female sunbed users under the age of 18 in EnglandJeffrey R Lake, Catherine S Thomson, Christopher J Twelves, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2011
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Jay D Naik, Christopher J Twelves, Peter J Selby, et al.Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.Breast Cancer Research and Treatment|January 20, 2016
Characterizing and quantifying the effects of breast cancer therapy using mathematical modelingWalter M Gregory, Christopher J Twelves, Richard Bell, et al.Cell Cycle (Georgetown, Tex.)|March 4, 2011
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumorsChristophe Massard, Jean-Charles Soria, D Alan Anthoney, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT databaseNadine J McCleary, Jeffrey A Meyerhardt, Erin Green, et al.Breast Cancer Research : BCR|February 8, 2016
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancerMarsela Braunstein, Linda Liao, Nicola Lyttle, et al.The Journal of Urology|September 6, 2006
Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancerRajiv Puri, Victor Palit, Paul M Loadman, et al.Pageof 2